LEADER 08183nam 22014653u 450 001 9910511992203321 005 20220210180416.0 010 $a92-4-069266-5 035 $a(CKB)3710000000198675 035 $a(EBL)1741841 035 $a(SSID)ssj0001401396 035 $a(PQKBManifestationID)12607341 035 $a(PQKBTitleCode)TC0001401396 035 $a(PQKBWorkID)11349928 035 $a(PQKB)10754181 035 $a(MiAaPQ)EBC1741841 035 $a(EXLCZ)993710000000198675 100 $a20140721d2014|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntimicrobial Resistance. Global Report on Surveillance$b[electronic resource] $eGlobal Report on Surveillance 210 $aGeneva $cWorld Health Organization$d2014 215 $a1 online resource (254 p.) 300 $aDescription based upon print version of record. 311 $a92-4-156474-1 327 $aCover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages 327 $a2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References 327 $aSECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment 327 $a4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses 327 $a4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine 327 $a5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material 330 $aThis WHO report produced in collaboration withMember States and other partners provides as accuratea picture as is presently possible of the magnitude ofAMR and the current state of surveillance globally.The report focuses on antibacterial resistance (ABR)in common bacterial pathogens. Why? There is amajor gap in knowledge about the magnitude of thisproblem and such information is needed to guideurgent public health actions. ABR is complex andmultidimensional. It involves a range of resistancemechanisms affecting an ever-widening range ofbacteria most of which can cause a wide spectrumof disea 606 $aDrug resistance -- Periodicals 606 $aDrug resistance in microorganisms 606 $aDrug resistance 606 $aAnti-infective agents$xClassification 606 $aDrug resistance in microorganisms$xEffect of drugs on 606 $aRisk management 606 $aRisk 606 $aRisk Management 606 $aInformation Science 606 $aDrug Resistance 606 $aMicrobiological Phenomena 606 $aEpidemiologic Measurements 606 $aTherapeutic Uses 606 $aProbability 606 $aPharmacologic Actions 606 $aPharmacological Phenomena 606 $aPublic Health 606 $aOrganization and Administration 606 $aStatistics as Topic 606 $aHealth Services Administration 606 $aEnvironment and Public Health 606 $aChemical Actions and Uses 606 $aPhysiological Phenomena 606 $aHealth Care Evaluation Mechanisms 606 $aHealth Care 606 $aEpidemiologic Methods 606 $aDrug Therapy 606 $aQuality of Health Care 606 $aInvestigative Techniques 606 $aDiagnostic Techniques and Procedures 606 $aHealth Care Quality, Access, and Evaluation 606 $aAnti-Infective Agents 606 $aClassification 606 $aRisk Assessment 606 $aDrug Resistance, Microbial 606 $aBiology$2HILCC 606 $aHealth & Biological Sciences$2HILCC 606 $aMicrobiology & Immunology$2HILCC 608 $aElectronic books. 608 $aPublication Formats 608 $aTechnical Report 615 4$aDrug resistance -- Periodicals. 615 4$aDrug resistance in microorganisms. 615 4$aDrug resistance. 615 0$aAnti-infective agents$xClassification 615 0$aDrug resistance in microorganisms$xEffect of drugs on 615 0$aRisk management 615 2$aRisk 615 2$aRisk Management 615 2$aInformation Science 615 2$aDrug Resistance 615 2$aMicrobiological Phenomena 615 2$aEpidemiologic Measurements 615 2$aTherapeutic Uses 615 2$aProbability 615 2$aPharmacologic Actions 615 2$aPharmacological Phenomena 615 2$aPublic Health 615 2$aOrganization and Administration 615 2$aStatistics as Topic 615 2$aHealth Services Administration 615 2$aEnvironment and Public Health 615 2$aChemical Actions and Uses 615 2$aPhysiological Phenomena 615 2$aHealth Care Evaluation Mechanisms 615 2$aHealth Care 615 2$aEpidemiologic Methods 615 2$aDrug Therapy. 615 2$aQuality of Health Care 615 2$aInvestigative Techniques 615 2$aDiagnostic Techniques and Procedures. 615 2$aHealth Care Quality, Access, and Evaluation 615 2$aAnti-Infective Agents 615 2$aClassification 615 2$aRisk Assessment 615 2$aDrug Resistance, Microbial 615 7$aBiology 615 7$aHealth & Biological Sciences 615 7$aMicrobiology & Immunology 676 $a616 700 $aOrganization$b World Health$0819556 702 $aWorld Health Organization 712 02$aWorld Health Organization 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910511992203321 996 $aAntimicrobial Resistance. Global Report on Surveillance$92552752 997 $aUNINA